What Broadview Ventures does

Broadview Ventures is a mission-driven venture capital firm founded in 2009 and backed by the Leducq Charitable Trust, a transatlantic foundation focused on cardiovascular disease. The firm invests exclusively in early-stage companies developing technologies for cardiovascular and neurovascular (stroke) indications, with a stated focus on seed and Series A rounds. Across its portfolio of 54 investments since inception, Broadview has targeted structural heart, heart failure, sleep apnea, hemostasis, and related modalities, sourcing opportunities globally across North America, Europe, Israel, Australia, and Canada.

The firm's core 'product' is structured seed and Series A capital combined with deep clinical and scientific domain support, leveraging the Leducq Foundation's global network of cardiovascular investigators. Longview Ventures, spun out in 2018, extends the firm's reach into Series B and later-stage follow-on financings, creating an integrated capital stack across early and growth stages for cardiovascular and stroke companies.

Economically, Broadview operates as a nonprofit-aligned investment vehicle rather than a conventional revenue-generating business. Capital is deployed from the foundation's endowment, and returns are realized through portfolio company exits and appreciation rather than management fees from external limited partners. The team is small and specialized, with recent senior promotions and advisory additions reinforcing succession and capacity for continued deal activity across the cardiovascular and stroke verticals.

Name

Broadview Ventures

Legal name

Broadview Ventures, Inc.

Website

https://broadviewventures.org

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Broadview Ventures is a foundation-backed venture capital firm investing in early-stage (seed and Series A) cardiovascular and stroke technology companies globally, supporting 54 portfolio investments since 2009.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital

NAICS

Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394)

SIC

Investment Advice (6282)

akta.pro primary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

akta.pro secondary industry

SDG / Thematic Sustainable Investment Funds (FSANAJAN)

Keywords

• Venture capital investing
• Cardiovascular technology
• Seed stage funding
• Medical device investment
• Biopharma investment

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Equity Investment Returns: Broadview Ventures generates returns through equity investments in portfolio companies. Returns are realized through exits via acquisitions, IPOs, or subsequent financing rounds. The firm has had multiple successful exits including acquisitions by Edwards Lifesciences, Boston Scientific, Rocket Pharma, Mesoblast, Biogen, and others.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Broadview Ventures provides seed and early-stage equity investments in companies developing innovative technologies for the diagnosis and treatment of cardiovascular disease and stroke. Operating as the investment vehicle of the Leducq Charitable Trust, the firm makes first institutional financings (typically Seed and Series A) across Therapeutics, Devices, Diagnostics, and Digital Health, with a complementary follow-on vehicle (Longview Ventures) supporting later-stage portfolio companies through Series B and Series C rounds.

Product overview

Broadview Ventures operates as a mission-driven investment organization focused on accelerating the development of cardiovascular and stroke technologies. Founded in 2009 and supported by the Leducq Charitable Trust, the firm provides seed and early-stage equity financing to companies across two primary technology categories: MedTech (medical devices including transcatheter implants, AI-enabled monitoring systems, and pacing technologies) and BioPharma (therapeutics including small molecules, RNA-based drugs, and biologics for cardiovascular and metabolic diseases). The investment strategy leverages global thought leaders in cardiovascular science and medicine, with Longview Ventures serving as a complementary follow-on investment vehicle for later-stage portfolio companies.

Differentiator

Problem solved

Functional benefit

Brands

• Longview Ventures: An independent investment vehicle launched in 2018 by the Leducq Trust to make follow-on investments in Broadview portfolio companies that are poised to achieve significant value-creating milestones with their next financing round. Focuses on clinical-stage companies, Series B to Series C, as a complement to Broadview's Seed and Series A investments.

Products and services

• Broadview Ventures Seed and Series A Equity Investment Seed and early-stage equity financing for companies developing innovative cardiovascular and stroke technologies across Therapeutics, Devices, Diagnostics, and Digital Health; targeted at first institutional financings with active board involvement and strategic/operational support.
• Longview Ventures Follow-on Equity Investment Series B to Series C follow-on equity investments in Broadview Ventures portfolio companies that have achieved significant value-creating milestones; designed to complement Broadview's Seed and Series A focus.
• Broadview MedTech Investment Portfolio Portfolio of medical device companies developing cardiovascular technologies including transcatheter heart failure treatment (Alleviant Medical), AI-enabled cardiac monitoring (Cardiosense), extravascular pacing systems (AtaCor Medical), and tricuspid regurgitation devices (CroíValve).
• Broadview BioPharma Investment Portfolio Portfolio of biopharmaceutical companies developing cardiovascular and metabolic therapeutics including GIPR antagonists for obesity (Antag Therapeutics), OSA treatment (Mosanna Therapeutics), intracranial hemorrhage treatment (Alveron Pharma), and RNA-based heart failure therapeutics (HAYA Therapeutics).

Quantifiable outcome

• 54 companies invested since 2009
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Deerfield Management: Healthcare-focused investment manager with broad life sciences and medical device coverage. Comparable to Broadview in its dedicated healthcare specialization and stage-agnostic approach, though substantially larger AUM and broader therapeutic scope.
• OrbiMed: Healthcare-dedicated investment firm spanning venture, growth, and credit across therapeutics, devices, and diagnostics. Comparable to Broadview in healthcare focus and global reach, but with much broader stage range and larger fund vehicles.
• RA Capital Management: Healthcare-focused investment manager with crossover, private, and public equity strategies. Comparable in cardiovascular and therapeutic-area expertise, though it operates across stages and public/private with much larger capital base.

Direct peers

• venBio: Early-stage life sciences venture firm focused on therapeutics. Highly comparable to Broadview in stage (seed/Series A), check size philosophy, and dedicated biotech focus, though Broadview adds a cardiovascular-only vertical plus devices and diagnostics.
• HealthCor Partners: Healthcare-focused investment manager across public and private markets. Comparable in therapeutic-area specialization and willingness to back early-stage clinical assets, though its mandate is broader and includes public equities.
• Atlas Venture: Early-stage life sciences venture firm creating and seeding biotech companies. Closely comparable to Broadview in stage preference (seed/Series A), therapeutic focus, and company-building orientation, though not cardiology-exclusive.
• Sofinnova Partners: European-based life sciences venture firm investing from seed through late stage. Comparable to Broadview in stage range, life sciences dedication, and European footprint, with overlapping cardiovascular exposure.
• 5AM Ventures: Early-stage life sciences venture firm focused on seed and Series A biotech. Comparable to Broadview in stage and life-sciences dedication; both build concentrated portfolios around platform technologies.

Others

• Edwards Lifesciences (corporate venture): Strategic acquirer in structural heart and critical care, and prior acquirer of Broadview portfolio company CardiAQ. Relevant as a strategic acquirer/corporate venture participant in the cardiovascular innovation ecosystem where Broadview invests.
• Boston Scientific (corporate venture): Major cardiovascular medtech incumbent and acquirer of Broadview portfolio company Apama. Relevant as a strategic exit partner and corporate venture participant overlapping Broadview's device investment universe.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/broadview-ventures-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments88 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Broadview Ventures